尿酸:跨越临床前与人体数据的脑保护转化之旅
尿酸是强内源性抗氧化剂,可中和过氧亚硝酸盐等活性物质对神经血管单元的毒性。急性缺血性卒中期间尿酸水平快速下降与更差预后相关,促使研究外源性尿酸补充的价值。多中心NIH卒中临床前评估网络(SPAN)按预设标准和严格方法学在6个独立实验室测试6种候选干预,尿酸补充是唯一在雄性和雌性动物、年轻小鼠、年轻大鼠、衰老小鼠、肥胖小鼠和自发性高血压大鼠中均超过预设疗效边界的干预。这一成果将使尿酸通过NIH StrokeNet血栓切除血管内平台进入关键临床试验。
要点
- 尿酸是强内源性抗氧化剂,可中和过氧亚硝酸盐等活性物质对神经血管单元的毒性。
- 急性缺血性卒中期间尿酸水平快速下降与更差卒中预后相关。
- SPAN中尿酸补充是唯一在雄性和雌性动物、年轻小鼠、年轻大鼠、衰老小鼠、肥胖小鼠和自发性高血压大鼠中均超过预设疗效边界的干预。
核心结论
- 尿酸补充在SPAN临床前评估中超过预设疗效边界,将通过NIH StrokeNet血栓切除血管内平台进入关键临床试验。
- 尿酸是机械取栓特别有吸引力的辅助干预,因其靶向限制该疗法疗效的微循环低灌注和氧化应激。
研究设计与样本
- 描述性综述,总结尿酸补充的转化开发历程。
- 多中心NIH卒中临床前评估网络(SPAN)按预设标准和严格方法学在6个独立实验室测试6种候选干预。
主要发现
- 尿酸补充是SPAN中唯一在雄性和雌性动物、年轻小鼠、年轻大鼠、衰老小鼠、肥胖小鼠和自发性高血压大鼠中均超过预设疗效边界的干预。
- 急性缺血性卒中期间尿酸水平快速下降与更差卒中预后相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Uric acid (UA) is a strong endogenous antioxidant that neutralizes the toxicity of peroxynitrite and other reactive species on the neurovascular unit generated during and after acute brain ischemia. The realization that a rapid reduction of UA levels during an acute ischemic stroke was associated with a worse stroke outcome paved the way to investigate the value of exogenous UA supplementation to counteract the progression of redox-mediated ischemic brain damage. The long translational journey for UA supplementation recently reached a critical milestone when the results of the multicenter NIH stroke preclinical assessment network (SPAN) were reported. In a novel preclinical paradigm, 6 treatment candidates including UA supplementation were selected and tested in 6 independent laboratories following predefined criteria and strict methodological rigor. UA supplementation was the only intervention in SPAN that exceeded the prespecified efficacy boundary with male and female animals, young mice, young rats, aging mice, obese mice, and spontaneously hypertensive rats. This unprecedented achievement will allow UA to undergo clinical testing in a pivotal clinical trial through a NIH StrokeNet thrombectomy endovascular platform created to assess new treatment strategies in patients treated with mechanical thrombectomy. UA is a particularly appealing adjuvant intervention for mechanical thrombectomy because it targets the microcirculatory hypoperfusion and oxidative stress that limits the efficacy of this therapy. This descriptive review aims to summarize the translational development of UA supplementation, highlighting those aspects that likely contributed to its success. It includes having a well-defined target and mechanism of action, and an approach that simultaneously integrated rigorous preclinical assessment, with epidemiologic and preliminary human intervention studies. Validation of the clinical value of UA supplementation in a pivotal trial would confirm the translational value of the SPAN paradigm in preclinical research.
引用
- Leira EC, Planas AM, Chauhan AK, et al. Uric Acid: A Translational Journey in Cerebroprotection That Spanned Preclinical and Human Data. Neurology. 2023. PMID: 37848338. doi:10.1212/WNL.0000000000207825
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。